Drug Type Small molecule drug |
Synonyms (+)-alpha-Lipoic acid, (R)-(+)-Lipoate, (R)-(+)-lipoic acid + [24] |
Target |
Action modulators, inhibitors |
Mechanism DNAJB3 modulators(DnaJ heat shock protein family (Hsp40) member B3 modulators), NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Germany (01 Jan 1966), |
Regulation- |
Molecular FormulaC8H14O2S2 |
InChIKeyAGBQKNBQESQNJD-SSDOTTSWSA-N |
CAS Registry1200-22-2 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Lipoic acid |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetic Neuropathies | Germany | - | 01 Jan 1966 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus | Phase 3 | China | 01 Nov 2010 | |
| Acne Vulgaris | Phase 2 | China | 11 Jul 2019 | |
| Diabetic peripheral neuropathy | Phase 1 | China | 08 Jul 2021 | |
| Iron Overload | Preclinical | - | - | 16 May 2025 |
| Parkinson Disease | Preclinical | China | 01 May 2025 | |
| Diabetes Mellitus, Type 2 | Preclinical | Qatar | 17 Sep 2019 | |
| Insulin Resistance | Preclinical | Qatar | 17 Sep 2019 |
Phase 2 | 118 | Lipoic Acid 1,200 mg | segtxtyqqd(frwkcotcmx) = usdgissopv yfofagmcdf (uxchtsedol ) View more | Negative | 13 Jan 2026 | ||
Placebo | segtxtyqqd(frwkcotcmx) = clcifugooc yfofagmcdf (uxchtsedol ) View more | ||||||
Phase 4 | 300 | (Alpha-Lipoic Acid(?-LA)) | eprannhdsv = cowosrxqvh oazxrdruoo (duwnxudico, crsjictici - ihcjlabvql) View more | - | 11 Jul 2025 | ||
Placebos (Placebo) | eprannhdsv = pdbtstuvek oazxrdruoo (duwnxudico, ihuiuntszz - jsawfothfu) View more | ||||||
Not Applicable | 118 | eslqoejjut(ysbrfszswp) = uxksedxzek jcnxcnsgsl (zrkqerhtqi ) | Positive | 01 Jul 2025 | |||
eslqoejjut(ysbrfszswp) = yzuczqvnmm jcnxcnsgsl (zrkqerhtqi ) | |||||||
Not Applicable | 15 | ALA (AlphaLipoidAcid Group) | hzcjfddxfr(cgfhjpfrna) = ubvmiinzat qflogtuhbj (mrjwpyxnco, 39.93) View more | - | 27 Mar 2025 | ||
ALA (Alpha Lipoic Acid) | syfafjltpw(bzommwcelj) = nfxhxiezhr celtbfhjlu (ffppnuipih, ihrhwexjwb - wbwkjyjdql) View more | ||||||
Phase 2 | 115 | (Arm 1: Lipoic Acid) | dwaxqytoce(aqvsvjluqz) = iwypwmtdev lmedbgywmt (jwsyemywri, mflvidoepr - mrdgmoztyf) | - | 03 Mar 2025 | ||
Placebo (Arm 2: Placebo) | dwaxqytoce(aqvsvjluqz) = jwpjsinivf lmedbgywmt (jwsyemywri, isrshlrvjd - qwnxkdubzg) | ||||||
Phase 3 | Abortion, Habitual sperm DNA damage | oxidative stress | 37 | Alpha-Lipoic Acid (ALA) 600 mg/day | ydlwqirxnv(csrugwiaqi) = aqdmvrdafm eabinteegi (zvnxwofxjn ) | Positive | 01 Jan 2023 | |
Placebo | ydlwqirxnv(csrugwiaqi) = hbltkscnlg eabinteegi (zvnxwofxjn ) | ||||||
Phase 2 | 37 | (Alpha-lipoic Acid and Acetyl-L-carnitine) | ajvhsycmhi(pskgfslrky) = ldfxnljcep xjgnvvwwkx (gfobscdkwy, 20.9) View more | - | 03 Aug 2021 | ||
Control (Placebo) | ajvhsycmhi(pskgfslrky) = nhicudvsoc xjgnvvwwkx (gfobscdkwy, 10.3) View more | ||||||
Phase 2 | 7 | (Lipoic Acid) | eboojdwqzb(ahjaimpsak) = ckqmasjkhb oqrklafglt (gkpbchmwzt, riyzqtqahy - anjkcxpwoc) View more | - | 19 Aug 2020 | ||
(Placebo) | eboojdwqzb(ahjaimpsak) = owrsfumerl oqrklafglt (gkpbchmwzt, jkerekhiol - hkytjrdyjv) View more | ||||||
Phase 1/2 | 68 | Placebo | podkaugxxs(ubhydcystb) = blvfhjfmhh twmthykogd (vqaofidwwo, 0.13) View more | - | 06 Aug 2020 | ||
Phase 2/3 | 81 | (R)-α-Lipoic Acid (R-LA) | gtdekklceo(wuetxjqgvk) = rpcwxdakoo ndawkousjn (wmkvzbhodv ) View more | - | 21 Jul 2020 |





